ArticleScience immunology2023
Lung tumor-infiltrating T
Open access · greenAbstract read
In one paragraph
Article in Science immunology, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 57 papers, 2 of them syntheses that pooled it.
0numbers the graph read from it
0cells of the map it votes in
57citing papers in PubMed, 2 pooled it
14.0field-weighted citation impact, top 1% of its field
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
57 citing papers in PubMed, 2 syntheses or guidelines pooled it, 61 citations in OpenAlex.
- T-bet: biological functions, molecular mechanisms, and therapeutic applications: a systematic review.Frontiers in immunology · 2026Pooled it
- Mapping research trends in macrophage polarization and immunotherapeutic potential in prostate cancer: a bibliometric and visual analysis.Frontiers in oncology · 2026Pooled it
- Depletion of Effector Regulatory T Cells Associates with Major Response to Induction Dual Immune Checkpoint Blockade.Cancer discovery · 2025Trial
- PD-1 genetic fate mapping uncovers immune cell diversity mediating the efficacy of combined PD-1 blockade and chemotherapy.Oncoimmunology · 2026Article
- Article
- Article
- Fc-optimized GITR antibody enhances a CD4 T cell-dendritic cell crosstalk to promote antitumor immunity.Nature cancer · 2026Article
- Molecular heterogeneity and clonal origin of CCR8Nature communications · 2026Article
- Deciphering lung cancer at high resolution: a narrative review of applications of single-cell and spatial transcriptomics sequencing.Translational lung cancer research · 2026Review
- Exploring the immune environment of glioblastoma in humanized mouse models.Neuro-oncology · 2026Article
- Transcription factors remodel tumor immune microenvironment by impacting multiple immune cells.Discover oncology · 2026Review
- Identification of cycling regulatory T cell precursors as conductors of immune escape during breast carcinoma progression.Cancer cell · 2026Article
- Regulatory T cells in cancer and inflammation.Signal transduction and targeted therapy · 2026Review
- The Treg-cell death axis in lung cancer: implications for immune evasion and novel therapeutic strategies.Molecular cancer · 2026Review
- Trajectory-guided dimensionality reduction for multi-sample single-cell RNA-seq data reveals biologically relevant sample-level heterogeneity.Bioinformatics (Oxford, England) · 2026Article
- Novel Insights into the Role of circRNAs in Cancer Immunotherapy Resistance and Clinical Implications.International journal of molecular sciences · 2026Review
- Article
- Targeting inflammatory microenvironments: overcoming therapy resistance and immunosuppression.Molecular cancer · 2026Review
- Regulatory T Cell Heterogeneity in the Steady State and Tumor.Immune network · 2026Review
- SAMHD1 drives immunosuppression in non-small cell lung cancer by promoting macrophage infiltration and restricting oncolytic adenovirus replication.Journal for immunotherapy of cancer · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
39 authors at 4 institutions in 2 countries.
Arbor G DykemaBloomberg-Kimmel Institute for Cancer Immunotherapy, Johns Hopkins School of Medicine, Baltimore, MD, USA.ORCID 0000-0001-5835-3261
Jiajia ZhangBloomberg-Kimmel Institute for Cancer Immunotherapy, Johns Hopkins School of Medicine, Baltimore, MD, USA.
Laurene S CheungBloomberg-Kimmel Institute for Cancer Immunotherapy, Johns Hopkins School of Medicine, Baltimore, MD, USA.ORCID 0000-0002-5759-9742
Sydney ConnorBloomberg-Kimmel Institute for Cancer Immunotherapy, Johns Hopkins School of Medicine, Baltimore, MD, USA.ORCID 0000-0002-0692-8008
Boyang ZhangDepartment of Biostatistics, Johns Hopkins Bloomberg School of Public Health, Baltimore, MD, USA.
Zhen ZengBloomberg-Kimmel Institute for Cancer Immunotherapy, Johns Hopkins School of Medicine, Baltimore, MD, USA.ORCID 0000-0002-3443-0637
Christopher M CherryCM Cherry Consulting, Baltimore, MD, USA.ORCID 0000-0002-5481-0055
Taibo LiDepartment of Biostatistics, Johns Hopkins Bloomberg School of Public Health, Baltimore, MD, USA.ORCID 0000-0002-6624-9293
Justina X CaushiBloomberg-Kimmel Institute for Cancer Immunotherapy, Johns Hopkins School of Medicine, Baltimore, MD, USA.
Marni NishimotoBloomberg-Kimmel Institute for Cancer Immunotherapy, Johns Hopkins School of Medicine, Baltimore, MD, USA.ORCID 0000-0002-0696-579X
Andrew J MunozBloomberg-Kimmel Institute for Cancer Immunotherapy, Johns Hopkins School of Medicine, Baltimore, MD, USA.ORCID 0000-0001-5118-1217
Zhicheng JiDepartment of Biostatistics and Bioinformatics, Duke University School of Medicine, Durham, NC, 27710, USA.
Wenpin HouDepartment of Biostatistics, Johns Hopkins Bloomberg School of Public Health, Baltimore, MD, USA.
Wentao ZhanDepartment of Biostatistics, Johns Hopkins Bloomberg School of Public Health, Baltimore, MD, USA.ORCID 0009-0002-1183-5305
Dipika SinghBloomberg-Kimmel Institute for Cancer Immunotherapy, Johns Hopkins School of Medicine, Baltimore, MD, USA.
Tianbei ZhangBloomberg-Kimmel Institute for Cancer Immunotherapy, Johns Hopkins School of Medicine, Baltimore, MD, USA.
Rufiaat RashidBloomberg-Kimmel Institute for Cancer Immunotherapy, Johns Hopkins School of Medicine, Baltimore, MD, USA.
Marisa Mitchell-FlackBloomberg-Kimmel Institute for Cancer Immunotherapy, Johns Hopkins School of Medicine, Baltimore, MD, USA.ORCID 0000-0003-3192-0865
Sadhana BomBloomberg-Kimmel Institute for Cancer Immunotherapy, Johns Hopkins School of Medicine, Baltimore, MD, USA.
Ada TamBloomberg-Kimmel Institute for Cancer Immunotherapy, Johns Hopkins School of Medicine, Baltimore, MD, USA.
Nick IontaBloomberg-Kimmel Institute for Cancer Immunotherapy, Johns Hopkins School of Medicine, Baltimore, MD, USA.
Thet H K AyeBloomberg-Kimmel Institute for Cancer Immunotherapy, Johns Hopkins School of Medicine, Baltimore, MD, USA.
Yi WangDepartment of Biostatistics, Johns Hopkins Bloomberg School of Public Health, Baltimore, MD, USA.
Camille A SawosikBloomberg-Kimmel Institute for Cancer Immunotherapy, Johns Hopkins School of Medicine, Baltimore, MD, USA.
Lauren E TiradoBloomberg-Kimmel Institute for Cancer Immunotherapy, Johns Hopkins School of Medicine, Baltimore, MD, USA.
Luke M TomasovicBloomberg-Kimmel Institute for Cancer Immunotherapy, Johns Hopkins School of Medicine, Baltimore, MD, USA.ORCID 0000-0002-1459-3252
Derek VanDykeDepartment of Chemical and Biomolecular Engineering, Johns Hopkins University, Baltimore, MD, USA.ORCID 0000-0002-0494-7184
Jamie B SpanglerBloomberg-Kimmel Institute for Cancer Immunotherapy, Johns Hopkins School of Medicine, Baltimore, MD, USA.ORCID 0000-0001-8187-3732
Valsamo AnagnostouBloomberg-Kimmel Institute for Cancer Immunotherapy, Johns Hopkins School of Medicine, Baltimore, MD, USA.ORCID 0000-0001-9480-3047
Stephen YangSidney Kimmel Comprehensive Cancer Center, Johns Hopkins School of Medicine, Baltimore, MD, USA.ORCID 0000-0003-2188-3407
Jonathan SpicerDepartment of Surgery, McGill University, Montreal, Canada.ORCID 0000-0003-2708-1309
Roni RayesDepartment of Surgery, McGill University, Montreal, Canada.
Janis TaubeBloomberg-Kimmel Institute for Cancer Immunotherapy, Johns Hopkins School of Medicine, Baltimore, MD, USA.ORCID 0000-0002-8273-4395
Julie R BrahmerBloomberg-Kimmel Institute for Cancer Immunotherapy, Johns Hopkins School of Medicine, Baltimore, MD, USA.
Patrick M FordeBloomberg-Kimmel Institute for Cancer Immunotherapy, Johns Hopkins School of Medicine, Baltimore, MD, USA.ORCID 0000-0001-6925-6344
Srinivasan YegnasubramanianBloomberg-Kimmel Institute for Cancer Immunotherapy, Johns Hopkins School of Medicine, Baltimore, MD, USA.ORCID 0000-0003-0744-6606
Hongkai JiDepartment of Biostatistics, Johns Hopkins Bloomberg School of Public Health, Baltimore, MD, USA.ORCID 0000-0002-6480-0141
Drew M PardollBloomberg-Kimmel Institute for Cancer Immunotherapy, Johns Hopkins School of Medicine, Baltimore, MD, USA.ORCID 0000-0001-6215-1013
Kellie N SmithBloomberg-Kimmel Institute for Cancer Immunotherapy, Johns Hopkins School of Medicine, Baltimore, MD, USA.ORCID 0000-0002-6295-8930
Bloomberg (United States) · USJohns Hopkins University · USMcGill University · CADuke University · US
Funding
Translational Research Central ServicesP30CA006973 · NCI · JOHNS HOPKINS UNIVERSITY · PI WILLIAM George NELSON · 1985 to 2026
$208.6MMedical Scientist Training ProgramT32GM136577 · NIGMS · JOHNS HOPKINS UNIVERSITY · PI ANDREA L COX · 2020 to 2026
$13.4MTRAINING IN AREAS FUNDAMENTAL TO CANCER RESEARCHT32CA009110 · NCI · JOHNS HOPKINS UNIVERSITY · PI MATUNIS, MICHAEL J., WEERARATNA, ASHANI T · 1985 to 2025
$13.1MPD-1/PD-L1 modulation in cancer therapyR01CA142779 · NCI · JOHNS HOPKINS UNIVERSITY · PI PARDOLL, DREW M., TAUBE, JANIS M · 2010 to 2025
$8.2MLarge-Scale Genetic Analyses of Human CancerR01CA121113 · NCI · JOHNS HOPKINS UNIVERSITY · PI ANAGNOSTOU, VALSAMO, VELCULESCU, VICTOR E. · 2006 to 2022
$4.3MImmunogenomic determinants of response and resistance to neoadjuvant anti-PD-1 in resectable NSCLCR37CA251447 · NCI · JOHNS HOPKINS UNIVERSITY · PI Kellie Nicole Smith · 2021 to 2026
$2.2MBig Data Methods for Decoding Gene RegulationR01HG009518 · NHGRI · JOHNS HOPKINS UNIVERSITY · PI JI, HONGKAI · 2018 to 2021
$1.7MImmunoengineered nanotechnology for targeted expansion of regulatory T cellsR01EB029455 · NIBIB · JOHNS HOPKINS UNIVERSITY · PI SPANGLER, JAMIE BERTA · 2020 to 2023
$1.7MComputational tools for regulome mapping using single-cell genomic dataR01HG010889 · NHGRI · JOHNS HOPKINS UNIVERSITY · PI JI, HONGKAI · 2019 to 2022
$1.6MComputational Methods for Inferring Single-cell DNA Methylation and its Spatial LandscapeK99HG011468 · NHGRI · JOHNS HOPKINS UNIVERSITY · PI HOU, WENPIN · 2021 to 2022
$168kNCI NIH HHS P30 CA006973NCI NIH HHS R01 CA121113NCI NIH HHS R01 CA142779NCI NIH HHS R37 CA251447NCI NIH HHS T32 CA009110NHGRI NIH HHS K99 HG011468NHGRI NIH HHS R01 HG009518NHGRI NIH HHS R01 HG010889NIBIB NIH HHS R01 EB029455NIGMS NIH HHS T32 GM136577
Abstract
Regulatory T cells (T
Indexed as
Carcinoma, Non-Small-Cell LungLung NeoplasmsAnimalsGranzymesHumansMiceSignal TransductionSingle-Cell AnalysisGranzymes
Identifiers
What OpenQuestion holds
Textmetadata
LicenceTDM
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.